Session information

Oral

[O26-1] O26-1: Immunosuppressive drugs: assey and genotyping

Tue. Sep 26, 2017 10:30 AM - 11:15 AM Room C1 (1F)

Chairs: Stein Bergan, Norway / Maria Shipkova, Germany

+Add all to schedule

[O26-1-1] Assessment of automated electrochemiluminescence immunoassay for everolimus

Kimitaka Suetsugu¹, Nanae Yamamoto², Yuichi Tsuchiya³, Kumi Matsukawa⁴, Tomohiro Shigematsu⁵, Nobuaki Egashira⁶, Satohiro Masuda⁷ (1.Kyushu University Hospital, 2.Kyushu University Hospital, 3.Kyushu University Hospital, 4.Kyushu University Hospital, 5.Kyushu University Hospital, 6.Kyushu University Hospital, 7.Kyushu University Hospital)

[O26-1-2] Long-term performance of laboratory developed LC-MS/MS tests and an FDA- approved immunoassay for the therapeutic drug monitoring of Everolimus

Bjoern Schniedewind¹, Uwe Christians², Eric J. Meyer³ (1.University of Colorado, 2.University of Colorado, 3.Pharmaceutical Corp.)

[O26-1-3] Is CYP3A5*3 genotyping for tacrolimus dosing really beneficial?

Tester F. Ashavaid¹, Swarup A. V. Shah², Alan Almeida³, Jatin Kothari⁴, Ashok Kirpalani⁵ (1.P.D. Hinduja National Hospital and Medical Research Centre, 2.P.D. Hinduja National Hospital and Medical Research Centre, 3.P.D. Hinduja National Hospital and Medical Research Centre, 4.P.D. Hinduja National Hospital and Medical Research Centre, 5.Bombay Hospital & Medical Research Centre)

▲